Immunotherapy and Blood Thinners, Heart Medicines and Diabetes Tablets — What Continues, What Gets Watched

Yes, in almost every case. Blood thinners, blood-pressure and heart tablets, diabetes tablets and injections and thyroid tablets are normally continued unchanged. Checkpoint-inhibitor immunotherapy is not broken down by the liver pathways behind most tablet-to-tablet interactions. What usually changes is how closely you are monitored, not what you are prescribed.

The fear usually runs the other way. Families arrive expecting a list of things to give up, and older patients on six or eight regular tablets assume cancer treatment means abandoning all of them. It does not. The heart, the blood pressure, the sugars and the thyroid do not pause while cancer is being treated.

So the single most important instruction here is also the simplest: do not stop a long-term medicine on your own, and do not let a relative stop it for you. A missed blood thinner or heart tablet has an immediate consequence of its own.

Medicines are described on this page by class, in everyday language, because the right decision depends on your own conditions and doses. Nothing here is a reason to change, hold or stop a prescription — every decision described is made by your treating team.

Four groups get watched more closely: blood thinners, diabetes medicines, thyroid tablets and long-term steroids or immune-suppressing medicines. None of them clashes chemically with immunotherapy. They are watched because an immune side effect can change the very thing the medicine was balancing, so a dose that was right last month may need review this month.

This table describes general patterns, not instructions for your prescription. Every group is named at class level, because the right answer depends on your own medicines and conditions.

Your medical oncologist coordinates, and at CION that happens through the tumour board and a single medicine list held by the treating team. Your physician, cardiologist or endocrinologist keeps prescribing and adjusting their own medicines. What must not happen is each doctor working from a different list.

In practice this is where things go wrong far more often than any drug interaction does. A cardiologist adjusts a dose and the oncology team hears three weeks later. A family doctor treats what looks like a stomach upset without knowing the patient is on immunotherapy. That is what happens when four people hold four versions of one list.

If you are organising treatment for an elderly parent, one job matters more than the rest: be the single owner of that list. Update it after every appointment with any doctor, keep it on your phone as well as on paper, and carry it to every visit.

For routine long-term medicines, no. Immunotherapy is given as a day-care infusion at our centres, and your usual tablets are normally taken on their normal schedule that morning, including on infusion day. The exceptions are medicines your team has specifically asked you to hold, and those instructions are given to you in writing.

Two points come up in almost every first consultation. The first is fasting. Patients assume an infusion needs an empty stomach and skip breakfast and their morning tablets. Ask your team what is expected on infusion day — skipping a meal while still taking a sugar-lowering medicine is a hazard in itself.

The second is procedures. A biopsy, a port insertion or a dental extraction may genuinely require a blood thinner to be paused for a short window. That is a real hold instruction: planned in advance, agreed between the doctor arranging the procedure and your treating team, and written down. A pause you arrange yourself on the day is not the same thing.

If a medicine is ever held, you should be able to say who asked for it, why, and when it restarts. If you cannot answer those three questions, call and ask before you skip a dose.

Because it does not behave like a tablet. Checkpoint-inhibitor immunotherapy is a large protein given into a vein. The body clears it the way it clears other proteins, not through the liver enzyme system that most tablets compete for. That is why the interaction charts people find online largely do not apply here.

Checkpoint-inhibitor treatment also does not attack the cancer directly. It releases a brake on your own immune cells so that they can. That explains both halves of this page: little competition with your other medicines, and a real need to watch anything the immune system touches.

So the risk moves. It stops being a chemistry question and becomes an overlap question. If the treatment inflames the thyroid, a thyroid tablet dose is no longer right. If it inflames the bowel, bleeding risk on a blood thinner looks different. If steroids are given for a side effect, sugars climb. The medicine has not interacted with anything — the body it was tuned to has changed.

This is the one situation where the answer is not simply carry on. Medicines that deliberately damp the immune system act against what immunotherapy is trying to do, and stopping them has its own risk. Whether immunotherapy is suitable at all is decided case by case, by your oncologist together with the specialist who prescribes them.

If you live with rheumatoid arthritis, an inflammatory bowel condition, psoriasis or a similar diagnosis, you are neither automatically excluded nor automatically suitable. The questions the team works through are how active the condition is now, how much immune suppression it needs, and what would happen if it flared.

Transplant recipients face a harder version of the same problem. The medicines protecting a transplanted kidney, liver or heart do exactly the job immunotherapy is designed to undo. The risk of rejection is real, and it is discussed openly with the transplant team before anything is decided.

Be honest about the evidence here. Both groups were largely excluded from the trials that established these treatments, and NCCN, ASCO and ESMO describe their guidance for them as limited data and expert consensus rather than strong trial evidence. That is not a reason to give up on the option. It is a reason to insist on a multidisciplinary discussion instead of a quick answer at one desk.

Ask for your case to go to a tumour board where the specialist managing that condition is consulted. At CION every patient goes to a tumour board as standard — you do not have to ask for it.

Five steps, in order. None of them asks you to decide anything about a medicine yourself. The aim is narrower and more useful: make sure every doctor treating you works from the same complete, current list.

1. 1

   Bring the boxes, not a memory

   Carry the actual strips, boxes and inhalers to the first appointment. Remembered names and doses are wrong more often than people expect.

2. 2

   Include what does not feel like medicine

   Vitamins, supplements, acidity tablets and over-the-counter painkillers belong on the list, as does anything from a traditional system of medicine. The ask is disclosure, not giving anything up.

3. 3

   Ask for the hold list in writing

   Ask which medicines, if any, need pausing, on which days, and when they restart. If the answer is none, that is a useful answer too — write it down.

4. 4

   Tell your other doctors you are on immunotherapy

   Say it before the prescription is written, every time — family doctor, dentist, cardiologist, emergency doctor. Do not assume it is already on their file.

5. 5

   Report changes instead of adjusting doses

   A climbing sugar reading, a slower pulse, a new bruise, unusual tiredness: information for your team, not problems to solve at home.

Routine medicines are one half of the sequencing question. The other half is how immunotherapy is ordered against your other cancer treatments.

• Immunotherapy and Hormone Treatment Together — for anyone on long-term hormone treatment, how the two are run alongside each other.
• Does Immunotherapy Make Later Chemotherapy Work Better? — the ordering question in the other direction, and what is known and not known.
• The Abscopal Effect: Can Radiation Make Immunotherapy Work Better? — where radiation fits in the sequence, and how established the effect is.
• Immunotherapy at CION Cancer Clinics — how immunotherapy is delivered as day care, and how patients with other long-term conditions are monitored between cycles.

One Team, One Medicine List, Every Cycle

Patients treated at CION are reviewed by a tumour board, so the doctors managing your other conditions are part of the plan rather than an afterthought.